Biofrontera (BFRI) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biofrontera (BFRI) has outperformed Vyome (HIND) over the past year, losing 10.1% versus a loss of 67.1%. Vyome is the larger company by market cap ($14.3 million vs $13.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | HIND |
|---|---|---|
| Share price | $0.9221 | $2.04 |
| Market cap | $13.70M | $14.32M |
| 1-day change | -1.42% | 0.00% |
| YTD return | +64.11% | -40.70% |
| 1-year return | -10.06% | -67.15% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 1.15 |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $1.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $6.56 |
| 52-week low | $0.555 | $1.75 |
| Distance from 52-week high | -44.45% | -68.90% |
| Average volume | 550.61K | 13.60K |
| Shares outstanding | 14.85M | 7.02M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed HIND by 57.1 percentage points over the past year.
BFRI vs HIND FAQ
Which is bigger, Biofrontera or Vyome?
Vyome (HIND) is larger, with a market capitalization of $14.32M compared with $13.70M for Biofrontera (BFRI).
Which stock has performed better over the past year, BFRI or HIND?
BFRI returned -10.06% over the past 12 months, compared with -67.15% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.